Condition: Acute Demyelinating Syndrome · Sponsor: Assistance Publique - Hôpitaux de Paris
Among all non viral encephalitis, myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) are the second most frequent diagnosis in children. Risk of relapses varies according to studied cohorts and cognitive and academic difficulties are more and more detected in children without knowing if these sequelae are related to the first attack or relapses. The hypothesis is that earlier treatment would induce reduction of sequelae after the first attack and the number of relapses which would be also associated with a subsequent reduction of disability occurrence on the long term.
This description comes directly from the study's public registry record.
Kumaran DEIVA, phD · 0145213112 · kumaran.deiva@aphp.fr
Domitille MOLINARI · 0145217138 · domitille.molinari@aphp.fr
Always discuss trial participation with your own doctor first.
| CHU Besançon | Besançon, France | Not Yet Recruiting |
| CHU Bordeaux | Bordeaux, France | Not Yet Recruiting |
| CHU Brest | Brest, France | Not Yet Recruiting |
| HCL de Bron | Bron, France | Not Yet Recruiting |
| Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Recruiting |
| CHRU Lille | Lille, France | Not Yet Recruiting |
| CHU Monptellier | Montpellier, France | Not Yet Recruiting |
| CHU Strasbourg | Strasbourg, France | Not Yet Recruiting |
| CHU Toulouse Purpan | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05545384